[{"id":"8f07f453-2b2f-43e3-acb3-b43491e93deb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00888615","created_at":"2021-01-18T03:24:06.456Z","updated_at":"2024-07-02T16:36:22.721Z","phase":"Phase 2","brief_title":"Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT00888615","lead_sponsor":"GOG Foundation","biomarkers":" CYP1A2","pipe":"","alterations":" ","tags":["CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • elesclomol (STA-4783)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 12/13/2010","start_date":" 12/13/2010","primary_txt":" Primary completion: 09/01/2011","primary_completion_date":" 09/01/2011","study_txt":" Completion: 08/31/2016","study_completion_date":" 08/31/2016","last_update_posted":"2021-10-20"}]